October 2, 2017. By Jane Mundy.
Washington, DC: Despite exhaustive studies that found an increased risk of amputation among Invokana diabetes patients, Janssen Pharmaceuticals has published its own version of research.Read [ New Invokana Research (Funded by Manufacturer) Disputes Earlier Studies Showing Amputation Risk ]
August 22, 2017. By Gordon Gibb.
Los Angeles, CA: When Janumet (sitagliptin and metformin combined) was approved by the US Food and Drug Administration (FDA) in 2007, the type 2 diabetes drug was within five years of achieving sales of $1.7 Billion. That year, when Janumet hit blockbuster status by 2012, the parent drug of Janumet – Januvia – earned $4 Billion for manufacturer Merck & Co. Januvia has been associated with Januvia side effects, and has resulted in Januvia cancer lawsuits.Read [ Janumet Patient Felled by Cancer of the Pancreas in 2012 ]
August 8, 2017. By Gordon Gibb.
Washington, DC: A drug indicated for the treatment of type 2 diabetes already carries warnings for compelling adverse reactions including a heightened risk for lower limb amputations, kidney failure, diabetic ketoacidosis and cardiovascular injuries. To that end, the FDA warns of fracture risk with Invokana and Invokamet. Yet in spite of such serious side effects associated with Invokana (canagliflozin) and Invokamet (canagliflozin and metformin), the US Food and Drug Administration (FDA) approved, last year an expanded indication for Invokamet.Read [ Are Risk of Invokana and Invokamet Bone Fractures a Sign of Fractured Regulations? ]
June 24, 2017. By Brenda Craig.
Philadelphia, PA Final results from two independent clinical trials indicate the amputation risk for users of the Type 2 Diabetes drug Canagliflozin, marketed as Invokana, Invokamet, Invokamet XR, are much greater than previously understood.Read [ FDA Black Box Warning Adds Fuel to Invokana Lawsuits ]
June 13, 2017. By Gordon Gibb.
Boston, MA: A new study recently published in the New England Journal of Medicine (06/08/17) with regard to the potential for diabetic ketoacidosis (DKA) shows that type 2 diabetes patients on sodium-glucose cotransporter 2 (SGLT2) inhibitor drugs appear to have double the risk for DKA when compared with patients using dipeptidyl peptidase-4 (DPP-4) inhibitors. Invokana is a member of the SGLT2 class, and ample concern has been expressed over Invokana linked with cardiovascular injuries and kidney failure.Read [ Invokana Adverse Events Subject to Much Scrutiny ]
May 18, 2017. By Gordon Gibb.
Washington, DC: An issue that looms even larger than that of Invokana linked with cardiovascular injuries and kidney failure is the potential for amputation associated with the diabetes drug. The issue first surfaced a year ago when the US Food and Drug Administration (FDA) issued an alert after studying the results of two clinical trials, warning that users of Invokana and Invokamet were twice as likely to require amputations of appendages, or limbs.Read [ Invokana to Get Black-Box Warning over Amputation Risk ]
April 15, 2017. By Gordon Gibb.
Trenton, NJ: We’re coming up to the first anniversary of a health and safety review conducted by Health Canada in May, 2016 with regard to Sodium-glucose cotransporter-2 (SGLT2) inhibitors: Invokana (canagliflozin), Forxiga (dapagliflozin), and Jardiance (empagliflozin). The move followed a similar review and a warning by the US Food and Drug Administration (FDA) with regard to the potential for cardiovascular injuries and kidney failure.Read [ Invokana Lawsuits Keep Trickling In ]
March 8, 2017. By Gordon Gibb.
Philadelphia, PA: A series of complex legal arguments and maneuvering with regard to jurisdictional issues may have served to briefly divert attention away from Invokana adverse events. However, plaintiffs are nonetheless steeled in their resolve to pursue compensation amidst allegations over Invokana linked with cardiovascular injuries and kidney failure.Read [ Invokana Lawsuits Will Remain in Federal Court In Philadelphia ]
February 8, 2017. By Gordon Gibb.
Trenton, NJ: It was about a year ago that the European Medicines Agency (EMA) raised the alarm over kidney problems associated with diabetes medication Invokana and other drugs in the SGLT2 class. This followed a warning the previous year from the Institute for Safe Medication Practices, which reported in 2015 its identification of some 457 serious adverse events involving kidney failure or impairment. Dehydration and fluid imbalances, kidney stones, urinary tract infections and abnormal weight loss were also identified. That led to various headlines suggesting Invokana Linked with Cardiovascular Injuries and Kidney Failure.Read [ Invokana Still Invoking Concerns ]
January 3, 2017. By Heidi Turner.
Trenton, NJ: Plaintiffs involved in Invokana lawsuits are celebrating now that at least some lawsuits have been consolidated for pretrial proceedings. The Invokana claims were filed against drug maker Johnson & Johnson and allege the company failed adequately test the drug before releasing it on the market and did not warn consumers about the risks associated with using the diabetes medication.Read [ Plaintiffs Celebrate Invokana Lawsuit Consolidation ]
- Judicial Panel Considers Consolidating Invokana Lawsuits By Heidi Turner (Dec-10-16)
- Janssen Loses One Invokana Battle By Heidi Turner (Nov-11-16)
- Plaintiffs Move to Consolidate Invokana Lawsuits By Heidi Turner (Oct-5-16)
- Invokana Lawsuits: Health Authorities Strengthen Warnings By Heidi Turner (Sep-6-16)
- Health Canada Updates Invokana Warning Ahead of the FDA By Gordon Gibb (Aug-1-16)
- FDA Strengthens Invokana Warnings By Heidi Turner (Jul-7-16)
- Invokana Floats Like a Butterfly, Stings Like a Bee By Gordon Gibb (Jun-5-16)
- Some Plaintiffs Develop DKA Mere Months after Starting Invokana By Gordon Gibb (May-31-16)
- More Invokana Lawsuits Filed By Heidi Turner (May-6-16)
- Diabetes Specialist Defends Invokana, Plaintiff Continues with Her Lawsuit Anyway By Gordon Gibb (Apr-3-16)
- Canadian Invokana Diabetes Patient Sues Janssen Pharmaceuticals By Brenda Craig (Mar-26-16)
- Invokana Goes to Court in Canada By Brenda Craig (Mar-24-16)
- Invokana Lawsuits Heating Up, Plaintiffs Allege Negligence By Gordon Gibb (Mar-8-16)
- Plaintiff Launches $1Billion Class-Action Invokana Lawsuit, Others Follow By Gordon Gibb (Feb-23-16)
- ISMP Questions Invokana Safety By Heidi Turner (Feb-12-16)
- Invokana Lawsuit Filed within days of Latest FDA Warning By Gordon Gibb (Jan-3-16)
- Invokana’s Deadly Side Effects Create the Opportunity for Major Recovery By The National Trial Lawyers (Dec-19-15)
- $1 Billion Invokana Lawsuit Filed in Canada By Heidi Turner (Dec-3-15)
- Consumer Group Concerned Over Off-Label Marketing of Invokana By Gordon Gibb (Nov-9-15)
- Additional Concerns Surface Over Invokana Side Effects: FDA By Gordon Gibb (Oct-4-15)
- FDA Warning Prompts Invokana Lawsuit Investigation By Heidi Turner (Aug-11-15)
- Invokana Problems Mount Just Two Years following FDA Approval By Gordon Gibb (Jul-6-15)
- Safety Review of SGLT2 Inhibitors Initiated by Health Canada By Lucy Campbell (Jun-22-15)